Document ID: FDA-2016-D-1254-0001
Agency: fda
Document Type: Notice
Title: Assessing Adhesion With Transdermal Delivery Systems and Topical Patches for Abbreviated New Drug Applications; Draft Guidance for Industry; Availability
Posted Date: 2016-06-01T04:00Z

[Federal Register Volume 81, Number 105 (Wednesday, June 1, 2016)]
[Notices]
[Pages 35025-35026]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-12822]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-D-1254]

Assessing Adhesion With Transdermal Delivery Systems and Topical 
Patches for Abbreviated New Drug Applications; Draft Guidance for 
Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
the availability of a draft guidance for industry entitled ``Assessing 
Adhesion with Transdermal Delivery Systems and Topical Patches for 
ANDAs.'' This draft guidance is intended to provide recommendations for 
the design and conduct of studies evaluating the adhesive performance 
of a Transdermal Delivery System or a topical patch (collectively, 
TDS). This guidance, once finalized, is intended to provide updated 
recommendations for the design and conduct of adhesion studies 
submitted in support of an Abbreviated New Drug Application (ANDA) for 
a TDS.

DATES: Although you can comment on any guidance at any time (see 21 CFR 
10.115(g)(5)), to ensure that the Agency considers your comment on this 
draft guidance before it begins work on the final version of the 
guidance, submit either electronic or written comments on the draft 
guidance by August 1, 2016.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: http://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to http://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on http://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Division of 
Dockets Management, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2016-D-1254 for ``Assessing Adhesion with Transdermal Delivery 
Systems and Topical Patches for ANDAs.'' Received comments will be 
placed in the docket and, except for those submitted as ``Confidential 
Submissions,'' publicly viewable at http://www.regulations.gov or at 
the Division of Dockets Management between 9 a.m. and 4 p.m., Monday 
through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential

[[Page 35026]]

with a heading or cover note that states ``THIS DOCUMENT CONTAINS 
CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including 
the claimed confidential information, in its consideration of comments. 
The second copy, which will have the claimed confidential information 
redacted/blacked out, will be available for public viewing and posted 
on http://www.regulations.gov. Submit both copies to the Division of 
Dockets Management. If you do not wish your name and contact 
information to be made publicly available, you can provide this 
information on the cover sheet and not in the body of your comments and 
you must identify this information as ``confidential.'' Any information 
marked as ``confidential'' will not be disclosed except in accordance 
with 21 CFR 10.20 and other applicable disclosure law. For more 
information about FDA's posting of comments to public dockets, see 80 
FR 56469, September 18, 2015, or access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Division of Dockets Management, 5630 Fishers 
Lane, Rm. 1061, Rockville, MD 20852.
    Submit written requests for single copies of the draft guidance to 
the Division of Drug Information, Center for Drug Evaluation and 
Research, Food and Drug Administration, 10001 New Hampshire Ave., 
Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one 
self-addressed adhesive label to assist that office in processing your 
requests. See the SUPPLEMENTARY INFORMATION section for electronic 
access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Kris Andre, Center for Drug Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 75, Rm. 4726, Silver Spring, MD 20993-0002, 240-402-7959.

SUPPLEMENTARY INFORMATION: 

I. Background

    FDA is announcing the availability of a draft guidance for industry 
entitled ``Assessing Adhesion with Transdermal Delivery Systems and 
Topical Patches for ANDAs.'' This draft guidance provides 
recommendations for the design and conduct of clinical studies 
evaluating the adhesive performance of a TDS submitted in support of an 
ANDA. The recommendations in this guidance relate exclusively to TDS 
adhesion studies submitted in support of an ANDA.
    The amount of drug delivered into and through the skin from a TDS 
is dependent, in part, on the surface area dosed. It is expected that 
the entire surface area of a TDS should remain consistently and 
uniformly adhered to the skin throughout the duration of wear under the 
conditions of use included in the product label. Under circumstances in 
which a TDS loses its adherence during wear, the amount of drug 
delivered to the patient may be reduced.
    During the course of the product's labeled wear period, a TDS is 
reasonably expected to encounter torsional strains arising from 
anatomical movements, changes in environmental temperature or humidity 
such as the daily exposure to water (e.g., during routine showering), 
and contact with clothing, bedding or other surfaces. TDS products that 
do not maintain consistent and uniform adhesion with the skin under the 
range of conditions experienced during the labeled wear period for the 
TDS can result in varying degrees of TDS detachment, including complete 
detachment, at different times during the course of product wear.
    When the adhesion characteristics of a TDS are not sufficiently 
robust, as evaluated against its labeled conditions of use, the TDS may 
exhibit variability in the area that is in contact with the skin. In 
such situations where a TDS is partially detached, there may be 
uncertainty about the resulting drug delivery profile and, hence, 
uncertainty about the rate and extent of drug absorption from the TDS. 
In addition, as the potential for complete detachment of the TDS 
increases, so does the risk of unintentional exposure of the drug 
product to an unintended recipient (e.g., a household member who may 
potentially be a child).
    This guidance describes the recommended approach to the adhesion 
clinical study design and, therefore, will supersede the 
recommendations related to adhesion studies provided in individual 
product-specific guidances published prior to the date of publication 
of this guidance. This guidance, once finalized, is intended to provide 
updated recommendations for the design and conduct of adhesion studies 
submitted in support of an ANDA for a TDS. FDA recommends that 
applicants consult this guidance in conjunction with any relevant 
product-specific guidance documents when considering other studies 
(e.g. irritation, sensitization) that may be necessary to support the 
bioequivalence (BE) of a proposed generic TDS drug product to its RLD.
    This draft guidance is being issued consistent with FDA's good 
guidance practices regulation (21 CFR 10.115). The draft guidance, when 
finalized, will represent the current thinking of FDA on ``Assessing 
Adhesion with Transdermal Delivery Systems and Topical Patches for 
ANDAs.'' It does not establish any rights for any person and is not 
binding on FDA or the public. You can use an alternative approach if it 
satisfies the requirements of the applicable statutes and regulations.

II. Electronic Access

    Persons with access to the Internet may obtain the draft guidance 
at either http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http://www.regulations.gov.

    Dated: May 26, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-12822 Filed 5-31-16; 8:45 am]
 BILLING CODE 4164-01-P